Maybe I'll tell you how I look at it in terms of post-market surveillance.
Basically, when a drug or health product is out on the market, we use a variety of means to collect information on that drug's use out in the market. Through MedEffect, through our Canadian adverse drug reaction newsletter, through any of the information we get through our compliance and enforcement activities, we gather the information, we assess it to look for signal checks in terms of what the data is telling us, and we liaise with our international counterparts as well as with our provincial and territorial counterparts within Canada. From that signal detection, we decide if any action is warranted, and we act upon it.
So post-market surveillance is basically the activities that do that, which is what we do in the marketed health products directorate that Dr. Turner is responsible for.